oral MEK1/2 inhibitor

Preclinical, oncology

from HTS and SBDD

J. Med. Chem.

Novartis Institutes for BioMedical Research

oral MEK1/2 inhibitor - Novartis Institutes for BioMedical Research

Context. MAP855 (Novartis Institutes for BioMedical Research) is an oral MEK1/2 active-site inhibitor. Several MEK inhibitors (e.g. cobimetinib, trametinib) have been approved for cancer, generally derived from the same…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: